Skip to main content
Premium Trial:

Request an Annual Quote

ProPhase Labs Acquires Personal Genome Sequencing Firm Nebula Genomics for $14.6M

NEW YORK — ProPhase Labs said on Wednesday that it has acquired direct-to-consumer genome testing firm Nebula Genomics for $14.6 million in stock and cash.

San Francisco-based Nebula, which was cofounded by Harvard University researcher George Church in 2017, offers a whole-genome sequencing test that provides diagnostic-ready data.

ProPhase said that Nebula will be integrated into its recently formed subsidiary ProPhase Precision Medicine, which focuses on genetic testing technologies, and that it will perform Nebula's DNA testing at its own CLIA lab.

ProPhase also said that Church has agreed to join the subsidiary's scientific advisory board and that he and other Nebula investors will convert their initial investments in the company into ProPhase Labs common stock.

Additional terms of the acquisition were not disclosed.

"The acquisition of Nebula fits our plan to better enable individuals who seek a better understanding of their predisposition to genetic-based diseases and guidance in the diagnosis of existing, genetically influenced conditions," ProPhase CEO Ted Karkus said in a statement.

During midday trading on the Nasdaq, shares of Doylestown, Pennsylvania-based ProPhase were down 11 percent at $6.82.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more